These results support the fact that downregulated miR-155 plays an essential role in the pathogenesis of drug resistance in MM through upregulation of both CD47 and TNFAIP8, and that it represents a promising therapeutic strategy [49]. This evidence concerns the gene TNFAIP8 and Miyoshi myopathy.